Which ACE inhibitor is known for decreasing mortality after myocardial infarction (MI)?

Enalapril is an angiotensin-converting enzyme (ACE) inhibitor that has been shown to reduce mortality in patients following a myocardial infarction (MI). This class of medications helps in several ways after an MI. They lower blood pressure, decrease the workload on the heart, and improve cardiac output. Enalapril specifically plays a crucial role in preventing the progression of heart failure and adverse remodeling of the heart muscle that can occur after an MI.

The effectiveness of enalapril in reducing mortality has been demonstrated in clinical trials, making it a standard part of post-MI management protocols. Its benefits primarily stem from the reduction in afterload (the resistance that the heart must work against) and preload (the volume of blood entering the heart). The longstanding use of ACE inhibitors, like enalapril, in the post-MI setting emphasizes their vital role in improving survival and outcomes for patients.

In contrast, the other options mentioned are not involved in the direct pharmacological treatment of myocardial infarction concerning mortality reduction. Propranolol, while a beta-blocker that is beneficial in managing heart rate and reducing progressive ischemia, does not specifically target mortality after MI in the same way. Naproxen and ibuprofen are non